Shah BD, Ghobadi A, Oluwole OO, et al. - This study was sought to present the pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study assessing the effectiveness and safety of the autologous anti-CD19 chimeric antigen receptor T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Researchers enrolled patients at 25 sites in the USA, Canada, and Europe. The study included 71 patients and had undergone leukapheresis between Oct 1, 2018, and Oct 9, 2019. According to the findings, KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete hematologic recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia, with the median overall survival not reached in responding patients, and a manageable safety profile. The data illustrate that KTE-X19 has the potential to confer long-term clinical benefit to these patients.